Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd (CLGN) is a clinical-stage regenerative medicine company specialising in recombinant human collagen (rhCollagen) produced using plant-based systems and platforms for 3D bioprinting. Its technology is used to develop medical devices, tissue repair products and bioinks for research and potential therapeutic applications. With a market capitalisation of around $30.14 million, CollPlant is a small-cap, higher-volatility stock where progress often hinges on technical milestones, partnerships and regulatory outcomes. Investors should be aware of typical biotech risks — clinical or regulatory setbacks, funding needs and potential share dilution — as well as the opportunities from growing demand for regenerative therapies and aesthetic applications. This summary is for general educational purposes only and is not personal financial advice. Always assess whether a speculative, micro-cap biotech fits your risk tolerance and seek independent advice if needed.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Collplant's stock, expecting its price to rise significantly to $11.
Financial Health
Collplant Biotechnologies is generating modest revenue and cash flow, indicating a stable financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CLGN
3D-Bioprinted Tissues
These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Bioprinting Potential
CollPlant’s focus on bioinks and 3D printing taps into a growing field of regenerative medicine, though commercialisation timelines can be lengthy and uncertain.
Small-cap Dynamics
With a market capitalisation near $30M, the stock can be highly volatile and sensitive to news; suitable only for investors comfortable with speculative positions.
Partnering Opportunities
Partnerships and licensing can accelerate market reach and revenue, yet reliance on collaborators and milestone-based income brings execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
